{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:07:19Z","timestamp":1790006839364,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"DOI":"10.1007\/s00115-026-02015-9","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:31:27Z","timestamp":1790004687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychopharmakologische Behandlung psychisch erkrankter Straft\u00e4ter","Psychopharmacological treatment of mentally ill offenders"],"prefix":"10.1007","author":[{"given":"N.","family":"Erlacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eusterschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Krimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Culmsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"#cr-split#-2015_CR1.1","unstructured":"DGPPN (2025) S3-Leitlinie Schizophrenie - Living Guideline"},{"key":"#cr-split#-2015_CR1.2","unstructured":"Version: 4.1 Fassung vom 17.10.2025. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-009. Zugegriffen: 14. Jan. 2026"},{"key":"2015_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00263","volume":"11","author":"C Farrell","year":"2020","unstructured":"Farrell\u00a0C, Brink\u00a0J (2020) The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample. Front Psychiatry 11:263","journal-title":"Front Psychiatry"},{"key":"2015_CR3","first-page":"88","volume":"30","author":"G Hefner","year":"2023","unstructured":"Hefner\u00a0G (2023) Antipsychotika-induzierte Dopamin-Supersensitivit\u00e4tspsychose bei psychiatrischen Patienten. Psychopharmakotherapie 30:88\u201395","journal-title":"Psychopharmakotherapie"},{"key":"2015_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke\u00a0C, Bergemann\u00a0N, Clement\u00a0HW et\u00a0al (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51:9\u201362","journal-title":"Pharmacopsychiatry"},{"key":"2015_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","volume":"11","author":"M H\u00f8jlund","year":"2024","unstructured":"H\u00f8jlund\u00a0M, K\u00f6hler-Forsberg\u00a0O, Gregersen\u00a0AT et\u00a0al (2024) Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis. Lancet Psychiatry 11:975\u2013989","journal-title":"Lancet Psychiatry"},{"key":"2015_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00963","volume":"10","author":"K Howner","year":"2019","unstructured":"Howner\u00a0K, Andine\u00a0P, Engberg\u00a0G et\u00a0al (2019) Pharmacological Treatment in Forensic Psychiatry\u2011A Systematic Review. Front Psychiatry 10:963","journal-title":"Front Psychiatry"},{"key":"2015_CR7","volume":"2010","author":"N Huband","year":"2010","unstructured":"Huband\u00a0N, Ferriter\u00a0M, Nathan\u00a0R et\u00a0al (2010) Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010:Cd003499","journal-title":"Cochrane Database Syst Rev"},{"key":"2015_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/22423982.2023.2218654","volume":"82","author":"S Lassen","year":"2023","unstructured":"Lassen\u00a0S, Heintz\u00a0T, Pedersen\u00a0T et\u00a0al (2023) Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients. Int J Circumpolar Health 82:2218654","journal-title":"Int J Circumpolar Health"},{"key":"2015_CR9","doi-asserted-by":"crossref","unstructured":"Machetanz L, Gunther MP, Lau S et\u00a0al. (2022) High Risk, High Dose?-Pharmacotherapeutic Prescription Patterns of Offender and Non-Offender Patients with Schizophrenia Spectrum Disorder. Biomedicines\u00a010","DOI":"10.3390\/biomedicines10123243"},{"key":"2015_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.722985","volume":"13","author":"G Mandarelli","year":"2022","unstructured":"Mandarelli\u00a0G, Carabellese\u00a0F, Di Sciascio\u00a0G et\u00a0al (2022) Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS). Front Psychol 13:722985","journal-title":"Front Psychol"},{"key":"2015_CR11","first-page":"429","volume":"21","author":"TZ Palijan","year":"2009","unstructured":"Palijan\u00a0TZ, Muzini\u0107\u00a0L, Radeljak\u00a0S (2009) Psychiatric comorbidity in forensic psychiatry. Psychiatr Danub 21:429\u2013436","journal-title":"Psychiatr Danub"},{"key":"2015_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11126-017-9521-z","volume":"89","author":"K Patchan","year":"2018","unstructured":"Patchan\u00a0K, Vyas\u00a0G, Hackman\u00a0AL et\u00a0al (2018) Clozapine in Reducing Aggression and Violence in Forensic Populations. Psychiatr Q 89:157\u2013168","journal-title":"Psychiatr Q"},{"key":"2015_CR13","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2025.10031","volume":"68","author":"TM Sitter","year":"2025","unstructured":"Sitter\u00a0TM, Virtanen\u00a0S, Edberg\u00a0H et\u00a0al (2025) Pharmacological treatment and psychiatric polypharmacy in forensic psychiatric care in Sweden. Eur Psychiatry 68:e78","journal-title":"Eur Psychiatry"},{"key":"2015_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03582-2","volume":"15","author":"M Spangemacher","year":"2025","unstructured":"Spangemacher\u00a0M, Schmitz\u00a0CN, Cumming\u00a0P et\u00a0al (2025) The sense and nonsense of antipsychotic combinations: A model for dopamine D(2\/3) receptor occupancy. Transl Psychiatry 15:348","journal-title":"Transl Psychiatry"},{"key":"2015_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-1540-5186","volume":"49","author":"S St\u00fcbner","year":"2022","unstructured":"St\u00fcbner\u00a0S, Yundina\u00a0E, Mu\u00dfmann\u00a0L et\u00a0al (2022) Psychotropic Drugs - Comparison of Application Practice in Forensic and General Psychiatry. Psychiatr Prax 49:255\u2013261","journal-title":"Psychiatr Prax"},{"key":"2015_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12505","volume":"45","author":"K Takeda","year":"2025","unstructured":"Takeda\u00a0K, Kashiwagi\u00a0H, Takanobu\u00a0K et\u00a0al (2025) Current status and features of antipsychotic prescriptions in Japanese forensic psychiatric wards based on a forensic inpatient database. Neuropsychopharmacol Rep 45:e12505","journal-title":"Neuropsychopharmacol Rep"},{"key":"2015_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen\u00a0J, Taipale\u00a0H, Meht\u00e4l\u00e4\u00a0J et\u00a0al (2019) Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry 76:499\u2013507","journal-title":"JAMA Psychiatry"},{"key":"2015_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14789949.2017.1332773","volume":"29","author":"N Vasic","year":"2018","unstructured":"Vasic\u00a0N, Segmiller\u00a0F, Rees\u00a0F et\u00a0al (2018) Psychopharmacologic treatment of in-patients with schizophrenia: Comparing forensic and general psychiatry. Journal of Forensic Psychiatry & Psychology 29:1\u201315","journal-title":"Journal of Forensic Psychiatry & Psychology"},{"key":"2015_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-3-7091-1849-8_9","volume-title":"Polypharmazie in der Behandlung psychischer Erkrankungen","author":"JG Witzel","year":"2016","unstructured":"Witzel\u00a0JG (2016) Kombinationen in der Behandlung forensischer Patienten. In: Messer\u00a0T, Schmau\u00df\u00a0M (Hrsg) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer Vienna, Vienna, S\u00a0235\u2013255"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02015-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02015-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:31:30Z","timestamp":1790004690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-02015-9"}},"subtitle":["Eine Stichtagsanalyse forensisch psychiatrisch untergebrachter Patienten aus zwei hessischen Ma\u00dfregelvollzugskliniken","A\u00a0sample survey of forensic psychiatric patients admitted to two forensic psychiatric facilities in Hesse"],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":20,"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-02015-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Hahn ist als Referentin f\u00fcr die Firmen Boehringer-Ingelheim Pharma GmbH, Recordati Pharma GmbH, Janssen-Cilag GmbH, Otsuka Pharma GmbH und Rovi GmbH t\u00e4tig und erh\u00e4lt ein Beraterhonorar von den Firmen Boehringer-Ingelheim Pharma GmbH und Rovi GmbH. C.\u00a0Culmsee gibt Referenten- und Beratert\u00e4tigkeiten f\u00fcr die Rovi GmbH an. N.\u00a0Erlacher, B.\u00a0Eusterschulte und S.\u00a0Krimmer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}